Isoniazid Alliance Pharmaceuticals

Isoniazid, the active ingredient in Isoniazid Alliance Pharmaceuticals, is an antitubercular agent presented as a sterile injectable for intramuscular, intrapleural, and intrathecal use. It is employed in the treatment and prevention of tuberculosis in patients requiring parenteral therapy.

GNH USA supplies Isoniazid Alliance Pharmaceuticals as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product conforms to EU quality standards and is manufactured under GMP conditions.

Isoniazid is used within the antitubercular drug class to target Mycobacterium tuberculosis infection.

- Active tuberculosis: Used as part of multi‑drug therapy to eradicate Mycobacterium tuberculosis. - Latent tuberculosis infection: Administered to prevent progression to active disease. - Post‑exposure prophylaxis: Given to individuals with recent exposure to TB to reduce risk of disease development.

Isoniazid may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Hepatotoxicity: Elevated liver enzymes and possible jaundice. - Peripheral neuropathy: Tingling or numbness, especially in the extremities. - Nausea and vomiting: Gastrointestinal discomfort. - Rash or mild skin eruptions.

Serious or Rare Side Effects: - Severe hepatitis: Acute liver failure requiring immediate medical attention. - Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Anaphylactic reaction: Rapid onset of airway compromise. - Seizures: Particularly in patients with pre‑existing CNS disorders. - Agranulocytosis: Marked reduction in white blood cells. - Lupus‑like syndrome: Autoimmune manifestations.

When prescribing isoniazid, clinicians should observe several safety considerations to minimize risk.

- Liver function monitoring: Perform baseline and periodic hepatic enzyme tests. - Vitamin B6 supplementation: Co‑administer pyridoxine to reduce peripheral neuropathy. - Avoid in known hypersensitivity: Discontinue if allergic reaction occurs. - Caution in neuropathy: Assess for pre‑existing peripheral nerve disorders before use. - Pregnancy and lactation: Evaluate risk‑benefit, as safety data are limited. - Store at ambient temperature: Keep in original container, protect from moisture and light.

Isoniazid can affect, and be affected by, several concomitant medicines.

Major Interactions (Avoid): - Rifampicin: Induces hepatic enzymes, reducing isoniazid plasma levels. - Alcohol: Increases risk of hepatotoxicity when combined with isoniazid. - Phenytoin: May potentiate neurotoxic effects.

Moderate Interactions (Monitor Closely): - Carbamazepine: May enhance hepatic metabolism, lowering efficacy. - Sulfonamides: Combined use can increase hepatic strain. - Pyrazinamide: Co‑administration may raise the incidence of liver injury.